Sharon A. O’Toole

This study shows that nanoparticle-delivered PD-L1 inhibitor enhances γδ T cell killing of platelet-cloaked ovarian cancer cells in vitro.

This study designs and tests Trojan Horse compounds targeting metabolic vulnerabilities in prostate cancer, showing promising cytotoxicity and selectivity in PCa cell lines.

This study compares five CTC isolation technologies in lung cancer, finding CellMag and Parsortix PR1 have the highest recovery rates.